Cart is empty The controversial 2021 decision by the government drug-buying agency Pharmac to prioritize Māori and Pacific patients in its funding of two game-changing new diabetes drugs appears to have paid off.
The controversial 2021 decision by the government drug-buying agency Pharmac to prioritize Māori and Pacific patients in its funding of two game-changing new diabetes drugs appears to have paid off.
Leave A Comment